Answers are grounded in this paper and cite their sources.
Despite the widespread use of seasonal influenza vaccines, the high antigenic variability of influenza A viruses necessitates the development of recombinant vaccines capable of eliciting broadly cross-protective immune responses. Conserved peptide antigens of the influenza A virus represent promising targets for the development of such vaccines. However, these antigens are poorly immunogenic and therefore require efficient presentation platforms to enhance their immunogenicity. Virus-like particles (VLPs) assembled from bacteriophage capsid proteins (CPs) constitute a promising platform due to their ability to display antigens at high density. In this study, chimeric VLPs were constructed using the Beihai32 bacteriophage capsid protein as a scaffold. Three conserved neuraminidase epitopes, two copies of the conserved hemagglutinin stalk fragment (HA2), and four copies of the M2e peptide (232 a.a. in total) were fused to the C-terminus of the CP. The recombinant protein was expressed in E. coli and self-assembled into spherical VLPs approximately 30 nm in size. ELISAs revealed that the M2e and HA2 peptides in the chimeric VLPs were accessible to specific antibodies, suggesting their surface exposure. Chimeric VLPs were recognized by anti-CP antibodies with less efficiency than VLPs formed by empty CP, indicating shielding of the CP core. Subcutaneous immunization of mice with the chimeric VLPs induced high titers of M2e- and HA2-specific IgG antibodies, as well as antibodies to neuraminidase epitopes. Thus, fusion of multiple influenza A virus antigens with the Beihai32 capsid protein enables the assembly of immunogenic VLPs, highlighting their potential as a platform for the development of recombinant influenza vaccines.
No takes yet. Share an insight, caveat, or question.
Zykova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: